Study resultsCase study

Glioma PDO 2.0: tumor features and treatment response

Tissue–PDO comparisons and lineage markers, plus CD31 and treatment readouts from a separate glioma study, show the model and functional data available for research.

Model & sampleTwo glioma PDO 2.0 studies

Study setupGBM identity profiling with complementary glioma treatment studies

AssaysIdentity profiling: H&E, Nestin, OLIG2 and S100B; complementary studies: CD31, early-apoptosis and necrosis readouts

STUDY EVIDENCE

Model identity, vascular context and treatment response

Complementary glioma studies show histology, lineage, CD31 and post-treatment apoptosis and necrosis.

01Histology and lineage

Source-tissue and PDO histology and markers

H&E, Nestin, OLIG2 and S100B characterize the GBM tissue and PDO.

02Vascular profiling

H&E and CD31 staining in glioma PDO 2.0

H&E and CD31 staining show tissue, PDO and vascular context in a complementary glioma study.

03Treatment response

Early apoptosis and necrosis under treatment

Early-apoptosis and necrosis percentages compare CTRL with four treatment groups.

View study figure set

Glioma PDO 2.0 model-profiling and functional-study figure set

The complete panel brings together GBM identity profiling with CD31 and treatment-response readouts from complementary glioma studies.

Study application

GBM histology and lineage profiling, together with CD31 and apoptosis/necrosis readouts from a complementary glioma study, inform model selection and candidate-response studies.

Related models and services

Explore related models and services

PROJECT DISCUSSION

Discuss a study for your program

Tell us which model, assay or finding you want to extend. Our scientists will adapt the approach to your candidate, samples and decision point.

Plan your study See how we work ↗